Efficacy Study of LIQUICURE™ to Treat Toe Nail Fungus
Launched by CHESSON LABORATORY ASSOCIATES, INC · Aug 14, 2009
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Nail fungal infection of at least one great toe \[per visual assessment, positive KOH preparation, and positive dermatophyte culture\]
- • Subjects who have target toenail showing 20-65% involvement as judged by the clinical investigator
- • 2 mm of clear nail proximally on great toenail / no lunula involvement
- • Subject must be physically able to reach toes to clean them and apply product
- • Subject is willing to discontinue use of other nail fungus treatment products and nail cosmetic products for duration of this study
- • Subject is willing and available to return for study follow up
- • Ability of the subject or legal representative to understand and provide signed consent for participating in the study
- • Negative urine pregnancy test for women of child bearing age
- • Females must be post menopausal or must agree to use approved contraceptives (actions, devices or medications to prevent or reduce the likelihood of pregnancy) throughout the study (Note: abstinence is NOT an accepted form of contraception)
- Exclusion Criteria:
- • Known hypersensitivity or allergy to the product materials
- • Negative KOH preparation or dermatophyte culture
- • Thickness of nail greater than 3 mm
- • Enrollment in another investigational drug or product protocol that would interfere with this study
- • Continuation or use of other topical or pharmaceutical treatments for the condition; a wash-out period of at least four weeks after discontinuation of a topical product or 180 days after discontinuation of an oral product for treatment of nail fungus is required
- • Chronic disease, including: diabetes, psoriasis, immune deficiency, severe foot injury, chronic vascular disease or any other condition that would decrease circulation to the extremities at the discretion of the investigator Pregnant or nursing females
- • Investigators, Chesson personnel, or Chesson Scientific Advisory Board members or their immediate family
About Chesson Laboratory Associates, Inc
Chesson Laboratory Associates, Inc. is a leading clinical trial sponsor dedicated to advancing medical research through innovative and rigorous study designs. With a focus on ensuring the highest standards of quality and compliance, the organization specializes in a wide range of therapeutic areas, facilitating the development of new treatments and therapies. Chesson Laboratory Associates, Inc. collaborates with pharmaceutical companies, biotechnology firms, and academic institutions to deliver comprehensive clinical trial management services, leveraging state-of-the-art technology and a team of experienced professionals to drive successful outcomes in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Raleigh, North Carolina, United States
Salisbury, North Carolina, United States
Cary, North Carolina, United States
Chapel Hill, North Carolina, United States
Patients applied
Trial Officials
Beth Goldstein, MD
Principal Investigator
Central Dermatology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials